Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103454 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
NCT00103454: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00103454 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 288 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103454, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).
Interventions
- DRUG GW685698X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
What the finished NCT00103454 record still lists
NCT00103454 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which GW685698X is the first listed.
NCT00103454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103454 about?
NCT00103454 is a clinical study titled "A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).". The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).
What is the current status of trial NCT00103454?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2005-01. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00103454?
The interventions under investigation include: GW685698X (DRUG).
Who is sponsoring clinical trial NCT00103454?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00103454's enrollment target sits among peer trials
288 1174th of 2000 higher than 819 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia